• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Eargo Appoints Katie Bayne to Board of Directors

    6/10/21 4:30:00 PM ET
    $EAR
    Medical Specialities
    Health Care
    Get the next $EAR alert in real time by email

    SAN JOSE, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the appointment of Katie Bayne to its Board of Directors, effective June 9, 2021. Ms. Bayne will serve as a member of the Nominating and Corporate Governance Committee. The appointment of Ms. Bayne fills the seat vacated by Juliet Tammenoms Bakker, following her resignation from the Board on June 9, 2021.

    Christian Gormsen, President and CEO, said, “We are incredibly fortunate to welcome Katie to the Eargo team. She is exceptionally qualified and brings decades of experience building one of the most recognizable brands in the world, Coca-Cola. We believe she will make significant contributions in continuing to build Eargo’s national and eventually global brand.”

    Josh Makower, MD, Chairman of the Board added, “Katie is a phenomenal addition to our Board. We believe she will help us accelerate executing one of our most important long term strategic initiatives: building the Eargo brand. We are fortunate to acquire this level of talent, and I am confident she will add tremendous value to our team. We would also like to thank Juliet for her contributions to the Board.”

    Ms. Bayne brings more than 30 years of consumer marketing and operations experience to her new position on the Board of Directors, including over two decades at The Coca-Cola Company, where she served as President of North America Brands and Chief Marketing Officer for North America. The Founder and President of strategic consulting and advisory firm Bayne Advisors, Ms. Bayne also serves as a Senior Advisor at Guggenheim Securities, LLC. She has also served as an independent director at Acreage Holdings since January 2021, where she serves on the Audit Committee and at Jessica Alba’s purpose-driven lifestyle brand, The Honest Company since November 2018, where she serves as Chair of the Compensation Committee and a member of the Audit Committee. She brings over a decade of public Board experience in varied industries, including retail.

    Ms. Bayne commented, “I have been extremely impressed with the way that Eargo has quickly established itself as a highly differentiated, disruptive player in the hearing health space. I look forward to working with the team to leverage the company’s solid foundation and recent growth as a launchpad for accelerating brand awareness and product adoption. The success of these initiatives will help us address the significant stigma and social isolation associated with hearing loss.”

    About Eargo
    Eargo is a medical device company dedicated to improving the quality of life of people with hearing loss. Our innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. We believe our Eargo hearing aids are the first and only virtually invisible, rechargeable, completely-in-canal, FDA regulated, exempt Class I or Class II devices for the treatment of hearing loss. Our differentiated, consumer-first solution empowers consumers to take control of their hearing. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from licensed hearing professionals via phone, text, email or video chat. The Eargo solution is offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels in the United States.

    The company’s 4th generation product, the Eargo Neo HiFi, was launched in January 2020 and features improved capabilities across audio fidelity and bandwidth. The Eargo Neo HiFi is available for purchase here.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding Ms. Bayne’s contributions to our Board, our strategic initiatives and accelerating brand awareness and product adoption. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks, uncertainties and assumptions related to: our expectations concerning additional orders by existing customers; our expectations regarding the potential market size and size of the potential consumer populations for our products and any future products, including our ability to maintain or increase insurance coverage of Eargo hearing aids; our ability to release new hearing aids and the anticipated features of any such hearing aids; developments and projections relating to our competitors and our industry, including competing products; our ability to maintain our competitive technological advantages against new entrants in our industry; the pricing of our hearing aids; our expectations regarding the ability to make certain claims related to the performance of our hearing aids relative to competitive products; our expectations with regard to changes in the regulatory landscape for hearing aid devices, including the implementation of the pending over-the-counter hearing aid pathway regulatory framework; and our estimates regarding the COVID-19 pandemic, including but not limited to, its duration and its impact on our business and results of operations. These and other risks are described in greater detail under the section titled “Risk Factors” contained in Eargo’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, are based on current expectations, forecasts and assumptions, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Related Links
    http://eargo.com

    Investor Contact
    Nick Laudico
    Vice President of Investor Relations
    [email protected]

    Media Contact
    Brad Sheets
    [email protected]

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c85e176-1d4c-4b25-bef4-cf0b575c3175


    Get the next $EAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EAR

    DatePrice TargetRatingAnalyst
    9/23/2021Outperform → Mkt Perform
    William Blair
    9/23/2021$11.00Overweight → Underweight
    JP Morgan
    9/23/2021$10.00Overweight → Equal-Weight
    Wells Fargo
    More analyst ratings

    $EAR
    Financials

    Live finance-specific insights

    See more
    • Eargo Reports Second Quarter 2023 Financial Results

      Recent Highlights: Net revenues of $8.1 million in the second quarter of 2023, up 12% year-over-yearGross systems shipped of 5,098, up 14% year-over-yearGAAP total operating loss $25.8 million in the second quarter of 2023, compared to $31.4 million in the second quarter of 2022In connection with the implementation of the announced cost reduction plan, the Company expects to extend net operating cash runway into the second half of 2024 SAN JOSE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported its financial results for the second quarter ended June 30, 2023. Will

      8/10/23 4:05:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Reports First Quarter 2023 Financial Results

      Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-yearGross systems shipped of 8,705, up 51% year-over-yearGAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023Company expects modest sequential improvements to net operating cash burn in the remaining quarters of 2023 SAN JOSE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported

      5/11/23 4:01:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo to Report First Quarter 2023 Financial Results on May 11, 2023

      SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the first quarter 2023 after market close on May 11, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2789592. The live webinar of the call may also be accessed by visiting the Events and Presentations s

      5/4/23 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

      SAN JOSE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- This quarter, Eargo, Inc. launches two new over-the-counter (OTC) hearing wellness devices, Eargo SE (launching today) and LINK by Eargo (launching in the first quarter of 2024). The new devices expand the brand's portfolio of offerings with a new earbud form factor and a completely-in-canal option focused on Eargo signature essentials. For over a decade, Eargo has set the industry standard for pairing award-winning discreet and effortless hearing devices with ongoing expert support. These newest devices address additional consumer needs around functionality, design and experience. Key highlights of each product include: Eargo SE (MSRP$1

      1/31/24 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Celebrates 1-Year Anniversary of FDA's Over-the-Counter (OTC) Hearing Aid Regulations, Driving a New Era of Accessibility and Innovation

      SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo") celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US. This important advancement by the US Food & Drug Administration (FDA), following a bipartisan mandate from Congress, was meant to reduce costs, increase competition, improve access, and drive innovation in the hearing aid category, resulting in more widespread adoption of hearing technology. This firmly aligns with Eargo's founding mission. The FDA has noted that the use of hearing aids has been associated with health benefits, improved social participation, and a better quality of life. Th

      11/1/23 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Expands Relationship with Best Buy, Growing In-Store Presence to Over 500 Locations

      SAN JOSE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced an expansion of its relationship with Best Buy. Eargo devices are now on display in more than 500 Best Buy stores, marking another step in Eargo's retail journey. Approximately 250 of these Best Buy locations will carry Eargo 5–an over-the-counter, FDA-cleared and self-fitting hearing aid–allowing customers to see Eargo's virtually invisible design and purchase in store. Additionally, customers can explore Eargo's full assortment of hearing aids on BestBuy.com. Through this expansion, Eargo continues

      10/26/23 4:01:00 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eargo downgraded by William Blair

      William Blair downgraded Eargo from Outperform to Mkt Perform

      9/23/21 7:17:15 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo downgraded by JP Morgan with a new price target

      JP Morgan downgraded Eargo from Overweight to Underweight and set a new price target of $11.00

      9/23/21 5:05:21 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Eargo from Overweight to Equal-Weight and set a new price target of $10.00

      9/23/21 5:03:59 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

      SC 13D/A - Eargo, Inc. (0001719395) (Subject)

      2/16/24 11:30:56 AM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

      SC 13D/A - Eargo, Inc. (0001719395) (Subject)

      10/30/23 5:21:26 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Eargo Inc. (Amendment)

      SC 13G/A - Eargo, Inc. (0001719395) (Subject)

      1/6/23 11:49:44 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Brownie William returned 296 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 6:03:54 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Narula Onkarr

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 6:01:45 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Wu David James returned 25,463 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 5:59:27 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Leadership Updates

    Live Leadership Updates

    See more

    $EAR
    SEC Filings

    See more
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Eargo Appoints Katie Bayne to Board of Directors

      SAN JOSE, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the appointment of Katie Bayne to its Board of Directors, effective June 9, 2021. Ms. Bayne will serve as a member of the Nominating and Corporate Governance Committee. The appointment of Ms. Bayne fills the seat vacated by Juliet Tammenoms Bakker, following her resignation from the Board on June 9, 2021. Christian Gormsen, President and CEO, said, “We are incredibly fortunate to welcome Katie to the Eargo team. She is exceptionally qualified and brings decades of experience building one of the mos

      6/10/21 4:30:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by Eargo Inc.

      15-12G - Eargo, Inc. (0001719395) (Filer)

      2/26/24 1:39:45 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Eargo Inc.

      S-8 POS - Eargo, Inc. (0001719395) (Filer)

      2/21/24 12:44:18 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Eargo Inc.

      S-8 POS - Eargo, Inc. (0001719395) (Filer)

      2/21/24 12:44:16 PM ET
      $EAR
      Medical Specialities
      Health Care